NEW YORK (GenomeWeb) – Adaptive Biotechnologies said today that it will collaborate with Amgen to use its next-generation sequencing-based immune repertoire profiling assay ClonoSeq to measure minimal residual disease in patients with multiple myeloma as part of a phase 3 clinical trial.
Amgen is sponsoring the trial and collaborating with Janssen. The trial compares progression-free survival between two drug combinations: Amgen's Kyprolis (carfilzomib), Janssen's Darzalex (daratumumab), and the corticosteroid hormone dexamethasone with a combination just carfilzomib and dexamethasone. Adaptive's ClonoSeq assay will be used to measure MRD status in patients with relapsed or refractory MM.
"Incorporating MRD measurement by the ClonoSeq assay offers Amgen the ability to accurately assess the depth of response generated by Kyprolis treatment in patients with relapsed or refractory MM,” Chad Robins, president, CEO and cofounder of Adaptive Biotechnologies, said in a statement.
The firm has struck previous agreements with both Amgen and Janssen. In June, Adaptive said it would work with Janssen to measure the efficacy of Janssen's Darzalex in MM.
And in January, Adaptive and Amgen said they planned to develop Adaptive's ClonoSeq assay to assess MRD in patients with acute lymphoblastic leukemia.